
    
      The study is divided into two parts. In Part A of the study, cohorts of subjects will be
      administered escalating doses of ORCA-010, using the 3+3 design. When the Maximum Tolerated
      Dose has been determined in Part A, a group of 12 new subjects will be treated in Part B of
      the study at this dose, with two administrations separated by a 2-week interval.
    
  